Frontiers in Science

Frontiers in Science is a peer-reviewed, open access journal that publishes original research articles as well as review articles in all areas of science and technology.


Alexandra Lucas

Editorial Board Member of Frontiers in Science

Professor, Department of Medicine and Department of Molecualr Genetics and Microbiology, University of Florida, USA

Research Areas

Vascular Disease, Sepsis, Virology, Inflammation, Atherosclerosis, Trasnpalnt

Education

1978-1982M.D.University of Alberta Edmonton, Alberta, Canada
1976-1978M.ScDepartment of Microbiology and Immunology University of Western Ontario, Canada
1970-1975B.ScBiochemistry McGill University Montreal, Quebec, Canada

Experience

2006-presentProfessor, Dept. of Medicine, Division of Cardiology College of Medicine, University of Florida And Malcom Randall VA Hospital Clinical Interventional Cardiologist
2006-presentEthel Smith Research Professorship College of Medicine, University of Florida
2006-presentCross Appointment, Professor, Department of Molecular Genetics and Microbiology, University of Florida
2006-2007Director, Vascular Biology Section Malcom Randall VA Medical Center, Gainesville, FL
2005-2006Associate Scientist, Program of Circulation Lawson Health Research Institute (LHRI)
2004-2006Cardiovascular Consultant for Kidney Pancreas Transplantation, London Health Sciences Centre
2003-2006Professor, Faculty of Medicine & Dentistry University of Western Ontario
1996-2003Associate Professor, University of Western Ontario
1994-1996Associate Professor, University of Alberta
1989-1994Assistant Professor, University of Alberta
1987-1987Summer Research Project Department of Biochemistry University of Alberta Supervisor: W. Schneider, MD.

Academic Achievement

First Class Honours, Biochemistry, McGill University 1975
Medical Research Council of Canada, Studentship, University of Western Ontario 1977-1978
Alberta Heritage Foundation for Medical Research (AHFMR), Part-time Studentship, University of Alberta 1981-1982
Chief Resident, Cardiology, University of Alberta 1986-1987
AHFMR Clinical Research Fellowship, Tufts' University 1987-1989
AHFMR Clinical Investigator, University of Alberta 1989-1996
American Society for Lasers in Surgery and Medicine, Award for Outstanding Research 1994
Featured Research American Heart Association 1995
Featured Article in Biophotonics Research 1999, 2005
Research Poster Reviewer 2000
First Degree Black Belt 2001
Second Degree Black Belt 2003
Third Degree Black Belt 2005
Renshynkan karate-Women's class instructor 2010
Delegate to Canadian Society of Atherosclerosis, Thrombosis and Vascular Biology 2001
S. Vaziri-Award for best student poster. Canadian Society for Atherosclerosis, Thrombosis and Vascular Biology Meeting 2002
Councilor, Canadian Society of Atherosclerosis, Thrombosis and Vascular Biology 2003
Academic Keys Who's Who in Medical Sciences Education (WWMSE) 2004
Symposia Chair-Canadian Society of Atherosclerosis, Thrombosis and Vascular Biology 2005
Prix Galien Award, Viron Therapeutics, Inc.(Dr. AR Lucas & Dr. G McFadden, Co-Founders) 2005
Ethel Smith Vasculitis Research Endowed Chair, College of Medicine, University of Florida 2006-Present
USC Teaching Honour Roll Award of Excellence, The University of Western Ontario 2006-2007
University of Florida Dept. of Medicine Research, Award for Dr. E. Dai poster presentation 2007
Shands Cardiac Cath Lab-Physician of the Month award 2007
University of Florida Dept. of Medicine, Award for Excellence in Teaching 2009

Membership

Canadian Cardiovascular Society
Alberta Cardiovascular Society
American Medical Association
Massachusetts Medical Society
American College of Cardiology
American Heart Association Basic Science Council
New York Academy of Science
Ontario Medical Association
Canadian Society of Atherosclerosis, Thrombosis and Vascular Biology
American Transplant Society
ISHLT-International Society of Hearth and Lung Transplantation
SPIE-The International Society for Optical Engineering
ASBMB-American Society for Biochemistry and Molecular Biology
Friends of Fort Liberté

Publications: Journals

[1]  Lucas AR, Flintoff W, Anderson R, Percy D, Coulter M, Dales S. In vivo and in vitro models of demyelinating diseases: tropism of the JHM strain of Murine hepatitis virus for cells of glial origin. Cell. 1977;12:553-560.
[2]  Lucas AR, Coulter M, Anderson R, Dales S, Flintoff W. In vivo and in vitro models of demyelinating diseases: II. Persistence and host-regulated thermosensitivity in cells of neural derivation infected with mouse hepatitis and measles viruses. Virology 1978;88:325-337.
[3]  Lucas AR, Klinke P. An unusual case of cardiomyopathy. Perspectives in Cardiology 1987;2:21-22.
[4]  Desnoyers MR, Isner JM, Pandian NG, Wang SS, Hougen T, Fields C, Lucas AR, Salem DM. Clinical and non-invasive hemodynamic results after aortic balloon valvuloplasty for aortic stenosis. Am J Cardiol 1988;12:1078-1084.
[5]  Isner JM, Fields CD, Lucas AR. Laser therapy for cardiovascular disease: Current status and future direction. Choices in Cardiology 1988;2:225-228.
[6]  Isner JM, Lucas AR, Fields CD. The role of laser therapy in the treatment of cardiovascular diseases. Br J Hosp Med. 1988;40:172-179.
[7]  Gaffney EG, Clarke RH, Lucas AR, Isner JM. The correlation of fluorescence emission with the plaque content and intimal thickness of atherosclerotic coronary arteries. Lasers Surg Med. 1989;9:215-228.
[8]  Gal D, Rongoine AJ, DeJesus ST, Lu E, Lucas AR, Isner JM. Yucatan microswine: evaluation of a new atherosclerotic animal model for the study of catheter based interventions. Am Heart J 1990;119:291-300.
[9]  Haraphongse M, Kunjara R, Burton J, Tymchak W, Lucas AR, Humen D, Montague TJ. The clinical efficacy of emergency bypass surgery for failed coronary angioplasty. Can J Cardiol. 1990;6:186-190.
[10]  Lucas AR, Lu E, Radosavijevic MJ, Gaffney EJ. The characterization of human coronary artery atherosclerotic plaque fluorescence emission. Can J Cardiol. 1990;6:219-228.
[11]  Lucas AR, Gauthier T, Isner JM, Clarke RH. Angiographic contrast media interference with laser-induced fluorescence excitation and detection in atherosclerotic human coronary arteries. Am Heart J 1991;121:110-118.
[12]  Perk M, Flynn GJ, Smith C, Bathgate B, Tulip J, Wen Y, Lucas AR. Laser-induced fluorescence emission: I. The spectroscopic identification of fibrotic endocardium and myocardium. Lasers Surg Med. 1991;112:523-534.
[13]  Lucas AR, Perk M, Wen Y, Tio F, Schneider W. Laser-induced fluorescence identification of intimal hyperplasia after intravascular stent implantation. The International Society of Optical Engineering, Diagnostic and Therapeutic Cardiovascular Interventions II, 1992;1642:183-190.
[14]  Lucas AR, Perk M, Wen Y, Smith C. Fluorescence spectroscopic detection of early injury-induced atherosclerosis. The International Society of Optical Engineering- Proceedings of Diagnostic and Therapeutic Cardiovascular Interventions II, 1992;1642:183-190.
[15]  Perk M, Flynn G, Gulamhusein S, Tulip J, Parfrey N, Lucas AR. Laser-induced fluorescence identification of sinoatrial and atrioventricular nodal conduction tissue. PACE 1993;16:1701-1712.
[16]  Yan WD, Perk, M, Nation PN, Power RF, Liu LY, Jiang X, Lucas AR. Fluorescence spectroscopic detection of virus-induced atherosclerosis. The International Society of Optical Engineering 1994;2130(11):74-81.
[17]  Yan WD, Perk M, Chagpar A, Wen Y, Stratoff S, Schneider WJ, Jugdutt BI, Tulip J, Lucas AR. Laser-induced fluorescence III. Quantitative analysis of atherosclerotic plaque content. Lasers Surg Med. 1995;16:164-178.
[18]  Lucas AR, Wen Y, Jiang XY, Liu LY, Yan WD, Bauer JA, Schneider W, Tulip J, Chagpar A, Dai EB, Perk M, Radosavijevic MJ, Montague P, Garbutt M. Development of an avian model for restenosis. Atherosclerosis 1996;119:17-41.
[19]  Bauer J, Jiang XY, Wen Y, Yan WD, Dai E, Liu LY, Tulip J, Lucas AR. Comparative study of Nd: YAG laser angioplasty at 1.06 µm, 1.32 µm, and 1.44 µm wavelengths: decreased vascular spasm and early mortality with 1.44 µm laser ablation. Lasers Surg Med. 1996;19:299-310.
[20]  Maksymowych WP, Nation N, Nash P, Macen J, Lucas AR, McFadden G, Russell AS. Amelioration of established antigen-induced arthritis in rabbits treated with a secreted viral serine proteinase inhibitor. J Rheumatol 1996;23:878-882.
[21]  Mossman K, Nation P, Mason J, Garbutt M, Lucas AR, McFadden G. Myxoma virus M-T7, a secreted homologue of the interferon gamma receptor, is a critical virulence factor for the development of myxomatosis in European rabbits. Virology 1996;215:17-30.
[22]  Dai E, Khoury S, Wishart D, Kay C, Jugdutt BI, Tulip J, Lucas AR. Laser-induced fluorescence: quantitative analysis of atherosclerotic plaque chemical content in human aorta. The International Society of Optical Engineering, Lasers in Surgery, Advanced Characterization of Therapeutics and Systems, 1996;2671:90-103.
[23]  Lucas AR, Liu LY, Macen J, Nash P, Dai E, Stewart M, Graham K, Etches W, Boshkov L, Nation PN, Lundstrom Hobman M, McFadden G. Virus-encoded serine proteinase inhibitor, SERP-1, inhibits atherosclerotic plaque development after balloon angioplasty. Circulation 1996;94:2890-2900.
[24]  Liu LY, Dai E, Lundstrom Hobman M, Kolodziejczyk D, Lucas AR. Animal models of restenosis: myth or reality. Current Pharmaceutical Design 1996;2:553-584.
[25]  Graham K, Lalani AS, Macen JL, Ness TL, Barry M, Liu LY, Lucas AR, Clark-Lewis I, Moyer RW, McFadden G: The T1/35kDa family of poxvirus secreted proteins bind chemokines and interfere with leukocyte influx into infected tissues. Virology 1997;229:12-24.
[26]  Jugdutt BI, Lucas AR, Khan MI, Blinston GE. Effect of angiotensin-converting enzyme inhibition on infarct collagen deposition and remodeling during healing after transmural canine myocardial infarction. Can J Cardiol 1997;13:657-668.
[27]  Dai E, Stewart M, Ritchie B, Mesali N, Raha S, Kolodziejczyk D, Lundstrom Hobman M, Liu LY, Etches W, Nation N, Michalak M, Lucas AR. Calreticulin, a potential vascular regulatory protein, reduces intimal hyperplasia after arterial injury. Arterioscler. Thromb. Vasc. Biol. 1997;17(11):2359-2368.
[28]  Lucas AR, Dai E, Liu LY, Perk M, Powers RF, Nation PN. Atherosclerosis in Marek's disease virus infected hypercholesterolemic roosters is reduced by HMGCoA reductase and ACE inhibitor therapy. Cardiovasc Res 1998;38:237-246.
[29]  Dzavik V, Burton JR, Kee C, Teo KK, Ignaszewski A, Lucas AR, Tymchak WJ. Changing practice patterns in the management of acute myocardial infarction complicated by cardiogenic shock: elderly compared with younger patients. Can J Cardiol. 1998;14(7):923-930.
[30]  Christov A, Dai E, Liu LY, Miller L, Nash P, Lalani AS, McFadden G, Nation PN, Tulip J, Lucas AR. Detection of transplant vasculopathy in a rat aortic allograft model by fluorescence spectroscopic optical analysis. Lasers Surg Med 1999;24:346-359.
[31]  Christov A, Liu LY, Lowe S, Icton C, Dunmore-Buyze J, Boughner DR, Dai E, Lucas AR. Laser-induced fluorescence (LIF)- recognition of the structural composition of porcine heart valves. Photochem Photobiol. 1999;69(3):382-389.
[32]  Lalani AS, Masters J, Graham K, Liu LY, Lucas AR, McFadden G. The role of the myxoma virus soluble T1 CC-chemokine inhibitor glycoprotein, M-T1, during myxoma virus pathogenesis. Virology 1999;256:233-245.
[33]  Hnatiuk S, Barry M, Zeng W, Liu L, Lucas A, Percy D, McFadden G: Role of the C-terminal RDEL motif of the myxoma virus M-T4 protein in terms of apoptosis regulation and viral pathogenesis. Virology 1999;263:290-306.
[34]  Clarke SE, Weinmann HJ, Dai E, Lucas AR, Rutt BK. Comparison of two blood pool contrast agents for 0.5 T MR angiography: experimental study in rabbits. Radiology 2000:214(3):787-794.
[35]  Christov A, Dai E, Drangova M, Liu L, Abela GS, Nash P, McFadden G, Lucas AR: Optical detection of triggered atherosclerotic plaque disruption by fluorescence emission analysis. Photochem Photobiol 2000;72(2):242-252.
[36]  Liu LY, Lalani A, Dai E, Seet B, Macauley C, Singh R, Fan L, McFadden G, Lucas AR: A viral anti-inflammatory chemokine binding protein, M-T7, reduces intimal hyperplasia after vascular injury. J Clin Invest 2000;105:1613-1621.
[37]  Miller LW, Dai E, Nash P, Liu L, Icton C, Klironomos D, Fan L, Nation PN, Zhong R, McFadden G, Lucas A: Inhibition of transplant vasculopathy in a rat aortic allograft model after infusion of anti-inflammatory viral serpin. Circulation 2000;101:1598-1605.
[38]  Hatton MWC, Ross B, Southward SMR, Lucas AR: Metabolism and distribution of the virus-encoded serine proteinase inhibitor, SERP-1, in healthy rabbits. Metabolism 2000;49(11):1449-1452.
[39]  Christov A, Kostuk WJ, Jablonsky G, Lucas AR: A three tiered fluorescence-based system for monitoring activation-related changes in human platelets. Biomedical Optics and Imaging, The International Society of Optical Engineering, Optical Biopsy and Tissue Optics 2000;4161:167-79.
[40]  Christov A, Dai E, Drangova M, Liu L, Abela GS, Nash P, McFadden G, Lucas AR: Laser-induced fluorescence spectroscopy (LFS): detection of unstable thrombogenic atherosclerotic plaque formation in a rabbit model- a first look diagnostic approach. . Biomedical Optics and Imaging, The International Society of Optical Engineering, Optical Biopsy and Tissue Optics 2000;4161:190-201.
[41]  Lucas AR, Dai E, Liu L, Guan H, Nash P, McFadden G, Miller L: Transplant vasculopathy: Viral anti-inflammatory serpin regulation of atherogenesis. J Heart Lung Transplant 2000;19:1029-1038.
[42]  Christov A, Kostuk WJ, Jablonsky G, Lucas AR: Fluorescence spectroscopic analysis of circulating platelet activation during coronary angioplasty. Lasers Surg Med 2001;28:414-426.
[43]  Zalai C, Kolodziejczyk D, Pilarski L, Christov A, Nation PN, Lundstrom Hobman M, Tymchak W, Dzavik V, Humen D, Kostuk W, Jablonsky G, Pflugfelder P, Brown J Lucas AR. Increased circulating monocyte activation in patients with unstable coronary syndromes J Am Coll Cardiol 2001;38:1340-1347.
[44]  Christov A, Dai E, Yan WD, Drangova M, Liu L, Abela GS, Nash P, McFadden G, Modry D, Gelfand E, Lucas AR: Optical detection of unstable plaque. Int J Cardiovasc Med Sci 2002; 4(1):97-109.
[45]  Christov A, Dai E, Liu L, Guan HY, Bernards MA, Cavers PB, Susko D, Lucas AR. Fluorescence spectroscopic analysis (FSA) detects quantitative changes in atherosclerotic plaque collagen and elastin content in vivo. The International Society of Optical Engineering, Atherosclerosis and Polarization. Proceedings of SPIE-Optical Biopsy IV 2003; 4613:89-94.
[46]  Lucas AR, Christov A, Dai E, Liu L, Nadeau B, Brown J. Circulating blood cells trigger acute inflammatory responses in the artery wall. The International Society of Optical Engineering, Atherosclerosis and Polarization. Proceedings of SPIE-Optical Biopsy IV 2003; 4613:95-100.
[47]  Dai E, Guan H, Liu L, Little S, McFadden G, Vaziri S, Cao H, Ivanova IA, Bocksch L, Lucas AR. Serp-1, a viral anti-inflammatory serpin, regulates cellular serine proteinase and serpin responses to vascular injury. J Biol Chem 2003; 278(20):18563-18572.
[48]  Bédard ELR, Kim P, Jiang J, Parry N, Liu L, Wang H, Garcia B, Li X, McFadden G, Lucas AR, Zhong R. Chemokine-binding viral protein M-T7 prevents chronic rejection in rat renal allografts. Transplantation 2003;76:249-252.
[49]  Wang H.; Jiang J.; McFadden G.; Garcia B.; Lucas AR.; Zhong R. Serp-1, a viral anti-inflammatory serpin, attenuates acute xenograft rejection in a rat-to-mouse cardiac transplantation model. Xenotransplant. 2003, 10(5): 506.
[50]  Li X, King E, Macaulay C, Lucas AR, McFadden G. Three Activity-Based Assays for Serp-1. BioProcess Int February 2003; 1(2): 48-55.
[51]  Korol R, Bikersteth J, Yang V, Dimov S, Marenttette D, Gordon M, Vitkin A, Liu L-Y,Canham P, Clarke S, Lucas AR. Semi-quantitative analysis of atherosclerosis using optical coherence tomography and time-of-flight secondary ion mass spectrometry. Prog Biomed Optics Imaging. Proceedings of SPIE, 2003;4(29): 212-220.
[52]  Bot I, von der Thusen JH, Donners MM, Lucas AR, van Berkel TJC, Kuiper J, Heeneman S and Biessen EAL. The Serine Protease Inhibitor Serp-1 Strongly Impairs Atherosclerotic Lesion Formation and Induces a Stable Plaque Phenotype in ApoE-/-Mice. Circ Res 2003, 93:464-471.
[53]  Liu LY, Dai E, Miller L, Seet B, Lalani A, McAuley C, Li X, Virgin HW, Bunce C, Turner P, Moyer R, McFadden G, Lucas AR. Viral chemokine binding proteins inhibit inflammatory responses and aortic allograft transplant vasculopathy in rat models. Transplantation 2004, 77(11):1652-1660.
[54]  Christov A, Korol R, Dai E, Liu L, Guan H, Bernards MA, Cavers PB, Susko D, Lucas AR. In vivo optical analysis of quantitative change in collagen and elastin during arterial remodeling. Photochem Photobiol 2005, 81: 457-466.
[55]  Cameron CM, Barrett JW, Liu LY, Lucas AR, McFadden G. Myxoma virus M141R expresses a viral CD200 (vOX-2) that is responsible for down-regulation of macrophage and T cell activation in vivo. J Virol 2005, 79(10):6052-6067.
[56]  Canham PB, Korol RM, Finlay HM, Hammond RR, Holdsworth D, Ferguson GG, Lucas AR. Collagen organization and biomechanics of the arteries and aneurysms of the human brain. G.A. Holzapfel, & R.W. Ogden (Eds.), Mechanics of Biological Tissue, Springer, Berlin, Germany: pp.307-322.
[57]  Cameron CM, Barrett W, Mann M, Lucas AR, and McFadden G. Myxoma virus M128L is expressed as a cell surface CD47-like virulence factor that contributes to the down-regulation of macrophage activation in vivo. J Virol 2005, 337:55-67.
[58]  Korol R, Canham P and Lucas AR. Multiple regression analysis. Biophotonics Int. 2005, 12(8):47-48.
[59]  Christov A, Liu L, Dai E, Yan WD, Boughner DR, Dunmore-Buyze J, Jugdutt B, Wishart D, Lucas AR: Fluorescence emission analysis (FEA)- Recognition of connective tissue composition of cardiovascular structures. Int J Cardiovasc Med Sci 2005 (In Press).
[60]  Bot I, von der Thusen JH, Donners MM, Lucas AR, van Berkel TJC, Kuiper J, Heeneman S and Biessen EAL. Serine Protease Inhibitor Serp-1 Strongly Impairs Atherosclerotic Lesion Formation and Induces a Stable Plaque Phenotype in ApoE-/-Mice. In Modulation of Atherothrombotic Factors: Novel Strategies for Plaque Stabilization. Print Partners Ipstamp, Enschede, The Netherlands 2005:pg 45-60. Published as part of a Thesis submission by Ilze Bot.
[61]  Viswanathan K, Bot I, Liu L, Dai E, Turner PC, Togonu-Bickersteth J, Pang B, Li Y, Biessen EA, Moyer R and Lucas AR. Viral cross-class serpin inhibits apoptosis, inflammation and atherosclerosis. In Modulation of Atherothrombotic Factors: Novel Strategies for Plaque Stabilization. Print Partners Ipstamp, Enschede, The Netherlands 2005:pg 61-76. Published as part of a Thesis submission by Ilze Bot.
[62]  Bédard ELR, Jiang J, Arp J, Qian H, Wang H, Guan H, Liu L, Parry N, Kim P, Garcia B, Li X, Macaulay C, McFadden G, Lucas AR and Zhong R. Prevention of chronic renal allograft rejection by SERP-1 protein. Transplantation 2006, 81:908-914.
[63]  Korol RM, Canham PB, Finlay HM, Hammond RR, Quantz M, Ferguson GG, Liu LY, Lucas AR. Optical detection of structural changes in human carotid atherosclerotic plaque. SPIE, 2005 (in press).
[64]  Dai E, Viswanathan K, Sun YM, Li X, Liu L, Togonu-Bickersteth B, Richardson J, Macaulay C, Nash P, Turner P, Nazarian S, Moyer R, McFadden G, Lucas AR. Identification of myxomaviral serpin reactive site loop sequences that regulate innate immune responses. J Biol Chem 2006, 281(12):8041-8050.
[65]  Viswanathan K, Liu L, Vaziri S, Richardson J, Togonu-Bickersteth B, Vatsya P, Christov A, and Lucas AR. Myxoma viral serpin, Serp-1, a unique interceptor of coagulation and innate immune pathways. Thromb Haemost 2006, 95:499-510.
[66]  Korol K, Finlay H, Josseau M, Lucas AR, Canham P. Fluorescence Spectroscopy and birefringence of molecular changes in maturing rat tail tendon. J Biomed Opt. 2007 12: 024011 PMID 17477726.
[67]  Goldberg A, Pakkiri P, Dai E, Lucas A, Fenster A. Measurement of aneurysm morphology determined by 3-d micro-ultrasound imaging as potential quantitative biomarkers in a mouse aneurysm model. Ultrasound Med Biol 2007;33:1552-1560.
[68]  Richardson M, Liu L, Dunphy L, Wong D, Sun Y, Singh K, Lucas A. Viral Serpin, Serp-1, inhibits endogenous angiogenesis in the chicken chorioallantoic membrane (CAM) model. Cardiovasc Pathol 2007;16(4): 191-202.
[69]  Bocksch L, Rider B, Stephens T, Dai E, Liu L, Diao H, Viswanathan K, Munuswamy-Ramunajam G, Singh B, Lucas A. C-Terminal Apolipoprotein E-Derived Peptide, Ep1.B, Displays Anti-Atherogenic Activity. Atherosclerosis 2007; 194: 116-124.
[70]  Jiang J, Kubelik D, Zassoko R, Liu W, Wise Y, Macaulay C, Garcia B, McFadden G, Lucas AR, Wang H. Prevention of innate immunity and induction of indefinite cardiac allograft survival by Serp-1 protein. Transplantation 2007; 84: 1158-1167.
[71]  Davids JA, Munuswamy-Ramunajam G, Liu LY, Dai E, Lucas A. Viral Anti-Inflammatory Proteins: The Potential for Immunotherapeutic Applications in Cancer. Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Inflammatory and Anti-Allergy Agents), June 2008. Vol. 7, No. 2: 130-149.
[72]  Li X, Schneider H, Peters A, Macaulay C, King E, Sun Y, Liu L, Dai E, McFadden G, Lucas A. Heparin alters viral serpin, serp-1, anti-thrombotic activity. Open Biochem J 2008; 2: 6-15.
[73]  Viswanathan K, Richardson J, Togonu-Bickersteth B, Dai E, Liu L, Vatsya P, Sun Y,  Yu J, Munuswamy-Ramunajam G, Baker H, Lucas AR. Myxoma Viral Serpin, Serp-1, Inhibits Human Monocyte Activation Through Regulation of Actin Binding Protein Filamin B. J Leukocyte Biol, 2009; 85: 418-426.
[74]  Bartee MY, Dai E, Liu L, Munuswamy-Ramanujam G, Macaulay C, McIvor D, McFadden G,. Lucas AR . M-T7: Measuring Chemokine-Modulating Activity. Methods in Enzymology, Chapter 10; Vol. 460, 2009: 209-228.
[75]  Munuswamy-Ramanujam G, Dai E, Liu LY, Schnabel M, Sun YM, Barker T, Satoh M, Bartee M, Lomas D, Lucas A. Serpins targeting thrombolytic proteases alter T helper lymphocyte sub population. Neuroserpin, a Thrombolytic Serine Protease Inhibitor (Serpin), Blocks Transplant Vasculopathy with associated potent anti-inflammatory and anti-atherogenic activity in mouse aortic allograft transplant models. Thrombosis Haemostasis, 2010; 103: 545-555.
[76]  Tardif J-C, L'Allier P, Grégoire J, Ibrahim R, McFadden G, Kostuk W, Knudtson M, Labinaz M, Waksman R, Pepine CJ, Macaulay C, Guertin M-C, Lucas A. A phase 2, double-blind, placebo-controlled trial of a viral Serpin (Serine Protease Inhibitor), VT-111, in patients with acute coronary syndrome and stent implant. Circ Cardiovasc Interv. 2010; 3: 543-548.
[77]  Korol RM, Canham PB, Viswanathan LL, Ferguson GG, Hammond RR, Finlay HM, Baker HV, Lopez C, Lucas AR. Detection of altered extracellular matrix in surface layers of unstable carotid plaque: an optical spectroscopy, birefringence and microarray genetic analysis. Photochem Photobiol 2011 (in press).
[78]  Dai E, Liu LY, Wang H, McIvor D, Sun YM, Macaulay C, King E, Munuswamy-Ramanujam G, Bartee MM, Charo I, McFadden G, Esko JD, Lucas AR. Chemokine : Glycosaminoglycan Interaction is a Pivotal Regulatory Step in Transplant Vascular Inflammation and Disease. PLoS One 2010; 5:e10510.
[79]  Nahid MA Rivera M, Lucas A, Chan EKL, Kesavalu L. Polymicrobial infection with periodontal pathogens specifically enhances miR-146a in ApoE-/-mice during experimental periodontal disease. Inflammation Immunity. 2011 (in press).
[80]  Chen H, Zheng D, Davids J, Bartee MY, Macaulay C, Thoburn R, Sobel E, Moyer R, McFadden G, Lucas AR. Viral Serpin Therapeutics: From Concept to Clinic. Methods Enzymol 2011 (in press).

Publications: Books/Book Chapters

[1]  Lucas AR, Wen Y, Perk M, Halliburton A, Klinke P. The development of a novel atherectomy catheter. ICUS Proceedings; Interventional Cardiology Update, Morton BC (Editor), Medicopea, 1992.
[2]  Nash P, Lucas AR, McFadden G. SERP-1, a poxvirus-encoded serpin, is expressed as a secreted glycoprotein that inhibits the inflammatory response to myxoma virus infection. In The Chemistry and Biology of Serpins, (Ed. FC Church), Plenum Publishing, New York, 1996.
[3]  Lucas AR, McFadden G: Harvesting viral proteins. CMAJ 1999;161(9):1134.
[4]  Bocksch L, Stephens T, Lucas AR, Singh, B. Apolipoprotein E: possible therapeutic target for atherosclerosis. Curr. Drug Targets: Cardiovasc. Haematol. Disord. 2001 Dec;1(2):93-106.
[5]  Zalai CV, Nash P, Dai E. Liu L, Lucas AR: The potential role of serine proteinase inhibitors for the prevention of plaque rupture. In Cardiovascular Plaque Rupture, Brown DL (Editor), Marcel Dekker, Inc., New York 2002, pages 447-482.
[6]  Christov, AM, Vitkin, A, Wilson, B, Lucas, AR. Optical analysis of Atherosclerotic Plaque. Recent Research Developments in Photochemistry and Photobiology, 2001, 5:95-129.
[7]  Bot I, von der Thusen JH, Lucas AR, Donners MMPC, Heeneman S, Fekkes ML, Kuiper J, Daemen MJAP, van Berkel JC, Biessen EAL. The Serine Protease Inhibitor Serp-1 Strongly Impairs De Novo Atherosclerotic Lesion Formation and Induces a Stable Plaque Phenotype in ApoE-/-Mice. In Preclinical Evaluation of Gene Therapeutic Approaches to Atherosclerosis: Towards a sustained anti-inflammatory strategy. Print Partners Ipstamp, Enschede, The Netherlands 2002: 111-119.
[8]  Seet BT, Johnston JB, Brunetti CR, Barrett JW, Everett H, Cameron C, Sypula J, Nazarian SH, Lucas AR, McFadden G. Poxviruses and Immune Evasion. Annu Rev Immunol 2003;21:377-423.
[9]  Togonu-Bickersteth B, Viswanathan K, Marentette D, Liu L, Vatsya P, Nadeau B and Lucas AR. Serp-1, a viral serpin with anti-inflammatory activity alters gene expression profiles in human monocytes. In International Proceedings of the 3rd World Congress on Heart Disease, Pathogenesis, Diagnosis and Treatment. A. Kimchi (Ed). July 12-15, 2003: 61-67.
[10]  Lucas AR. A Medical Mission to Fort Liberté, Haiti. The Medical Post, 2004:40(19):32-33.
[11]  Viswanathan K, Liu L, Turner PC, Dai E, Moyer RW, Lucas AR. Poxviral cross-class proteinase inhibitors alter arterial apoptotic response and reduce plaque growth. Proceedings of the 12th International Congress of Immunology and 4th Annual Conference of FOCIS, Immunology 2004.
[12]  Lucas AR, Dai E, Viswanathan K, Togonu-Bickersteth B, Richardson J, Liu LY, Macaulay C, McFadden G. Serpins- A link between the thrombolytic and innate immune response pathways. Proceedings of the 12th International Congress of Immunology and 4th Annual Conference of FOCIS, Immunology 2004.
[13]  Lucas AR, and McFadden G. Secreted immuno-modulatory viral proteins as novel biotherapeutics. Immunology 2004;173: 4765-4774.
[14]  Richardson J, Viswanathan K and Lucas, AR. Serpins, the Vasculature, and Viral Therapeutics. Frontiers in Bioscience, January 1, 2006, 11:1042-56.
[15]  Lucas, AR., McIvor, D. and McFadden, G. Virus-encoded chemokine modulators as novel anti-inflammatory reagents. In "Progress in Inflammatory Research" (Eds. K. Neote, G. Letts and B. Moser). Birkhauser Publishing, Basel, Switzerland, Vol. 1:pp 165-182 (2006).
[16]  Lucas A, Korol R, Pepine C. Inflammation in Atherosclerosis. Circulation 2006, 113:e728-732 (PMID 16651475)
[17]  Munuswamy-Ramunajam G, Khan KA, Lucas AR. Viral Anti-Inflammatory Reagents; The Potential for Treatment of Arthritic and Vasculitic Disorders. Endocrine, Metabolic and Immune Disorders: Drug Targets. 2006;6:331-343.2006.
[18]  Rahman MM, Lucas A, McFadden G. Viral TNF Inhibitors as Potential Therapeutics. Invited book chapter, Pathogen-Derived Immunomodulatory Molecules, Edited by Padraic Fallon, Landes Bioscience. (2008), Chapter 5, Pub Date: 2009-10-19.
[19]  Lucas A, Liu L, Dai E, Bot I, Viswanathan K, Munuswamy-Ramunajam G, Davids JA, Bartee MY, Richardson J, Christov A, Wang H, Macaulay C, Poznansky M, Zhong R, Miller L, Biessen E, Richardson M, Sullivan C, Moyer R, Hatton M, Lomas DA and McFadden G. The Serpin Saga; Development of a New Class of Virus Derived Anti-inflammatory Protein Immunotherapeutics in Pathogen-Derived Immunomodulatory Molecules, Edited by Padraic Fallon, Landes Bioscience. (2008), Chapter 11, Pub Date: 2009-10-19.
[20]  Kennedy KL, Lucas AR, Wan W. Local Delivery of Therapeutics for Percutaneous Interventions. Curr Drug Delivery 2011, in press.